Rich Pharmaceuticals (RCHA) 10-K 2017 FY Annual report

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Rich Pharmaceuticals, Inc. (the "Company") on Form 10-K for the period ending March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(a) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  September 1, 2017	/s/ Ben Chang
	Ben Chang, Chief Executive Officer
	(Principal Executive Officer) and Chief Financial Officer (Principal Accounting Officer)